I think the reason GC said update on lympro was because we're getting more than just data. We should get an update to the plan surrounding lympro too whether data is good or bad. Sure, he said 80% was floor, but I wouldn't be super surprised if we were lower or if things got messed up. Could be we get great news too.

I think this whole CEO change talk is premature by a couple days at least. You'll never get my list because if data and plan is good, I'm invested, and if data is bad, I'm gone, who care who runs AMBS then, it will not be a good investment for some time.